Skip to main content

01.12.2012 | Review | Ausgabe 1/2012 Open Access

Cancer Cell International 1/2012

Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Cancer Cell International > Ausgabe 1/2012
Jiangning Zhao, Zhenshu Xu, Delong Liu, Quanyi Lu
Wichtige Hinweise
Jiangning Zhao, Zhenshu Xu contributed equally to this work.

Competing interests

Authors have no relevant conflict of interest.

Authors’ contribution

DL and QL designed the study. All authors participated in data collection and draft preparation. All authors read and approved the final manuscript.


Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B –cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (fludarabine, cyclophosphamide, rituximab) has been shown to be better than fludarabine alone and fludarabine plus cyclophosphamide for IL. In FOLL05 trial, R-CHOP was compared with R-CVP (cyclophosphamide, vincristine, prednisone) and R-FM (fludarabine, mitoxantrone). The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (bendamustine, rituximab) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Cancer Cell International 1/2012 Zur Ausgabe